Increased human polo-like kinase-1 expression in gliomas

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Polo-like kinase 1 (PLK-1) is a serine/threonine kinase crucial for cell division, including spindle formation and chromosome segregation.
• PLK-1's role in cell proliferation suggests its potential involvement in cancer development and progression.

Purpose of the Study:

• To investigate the expression levels of PLK-1 in various grades of astrocytic tumors and human glioma cell lines.
• To explore the correlation between PLK-1 expression and proliferation markers like MIB-1.
• To examine the relationship between PLK-1 and Mitogen-activated Protein Kinase (MAPK) cascades using specific inhibitors.

Main Methods:

• Immunohistochemical detection of PLK protein in astrocytic tumors and glioma cell lines.
• Quantitative analysis of PLK-mRNA in tumor specimens.
• Treatment of glioma cell lines (U87MG, U118MG, U138MG) with specific inhibitors targeting MAPK pathways.
• Assessment of cell density and PLK-1 expression following inhibitor treatment.

Main Results:

• PLK-1 protein expression was significantly elevated in astrocytic tumors, with the highest levels observed in glioblastomas.
• A strong positive correlation was found between PLK-1 expression and MIB-1 nuclear immunoreactivity, a marker of cell proliferation.
• PLK-1 mRNA was detected in all investigated tumor samples, reinforcing its link to proliferation.
• While all tested MAPK inhibitors reduced cell density, only the PLCy inhibitor demonstrably decreased PLK-1 expression in U87MG, U118MG, and U138MG cell lines.

Conclusions:

• PLK-1 is highly expressed in astrocytic tumors, particularly glioblastomas, and its expression correlates with tumor grade and proliferation.
• PLK-1 plays a significant role in glioma cell proliferation, potentially through its interaction with MAPK pathways.
• Targeting PLCy may represent a viable therapeutic strategy for reducing PLK-1 expression and controlling glioma growth.